Five trans protesters disrupted a plenary session at the U.S. Conference on AIDS to share their deeply personal stories about fighting for acceptance within the HIV community.
HIV.gov shares their conversations with several presenters and participants at USCA 2017 about HIV-related stigma and curing hepatitis C coinfection among people living with HIV.
As HIV advocates descend on Washington, D.C., for a major community meeting, Charles Sanchez provides a first-hand view of the events that are unfolding -- and some of the people at their center.
$1 Million in Funding to Help HIV Organizations Impacted by Hurricanes Harvey and Irma Announced at USCA
Donated by Gilead Sciences, the $1 million fund to help HIV organizations impacted by Hurricanes Harvey and Irma was announced at the opening of the 21st annual U.S. Conference on AIDS in Washington, D.C.
Many trans women living with HIV may contract the virus because they or their sexual partners are intravenous drug users (IDU), finds a new study.
It turns out that you can trust gay men at high risk for HIV to take care of their health -- even if they have to remember to take an HIV prevention pill before sex.
Janssen Vaccines and Prevention B.V. is now rapidly advancing an experimental prime-boost HIV vaccine regimen, with plans announced to launch a large-scale "proof of concept" efficacy trial in women in late 2017/early 2018.
Dolutegravir (DTG) was superior to lopinavir/ritonavir (LPV/r) in a comparison of DTG-based regimen versus the WHO-recommended second-line regimen.
Brief IAS 2017 summaries of ongoing research on pre-exposure prophylaxis (PrEP), evaluating its long-term effectiveness and safety, patient experiences, and alternative dosing schedules, such as an on-demand regimen.
Two interesting early studies on the investigational NRTI MK-8591 (EFdA) were presented at IAS 2017. This compound is notable for a very high potency, a long-half life and the potential for use both as HIV treatment and for HIV prevention.